Printer Friendly Version

Quadex Labs Launches Revolutionary Professional–Grade Cold Sore Treatment

Viroxyn Professional Use Introduced to Oral Healthcare Industry at American Dental Association Annual Session

SAN FRANCISCO — October 19, 2012 — Quadex Labs, a healthcare research and product development company, announced today the release of Viroxyn Professional Use, a single application cold sore product available exclusively through healthcare professionals. The patented no–touch system contains 7.5% benzocaine to numb the site of the cold sore, making it possible to address the virus itself. This starts the healing process immediately, and provides the best clinical outcome per dose of any prescription or over–the–counter (OTC) cold sore medication.

"Patients are increasingly turning to their dentists for overall healthcare issues. And cold sores are not a trivial issue, whether it is because of appearance, pain, or the possibility of contagion," Neil Romano, president and CEO of Quadex Labs, said. "Dentists are the most likely to see cold sores, and now they have a guaranteed, effective treatment that returns their patients to their normal lifestyle in a dramatically reduced period of time."

Viroxyn1 is listed as a standard of care in many dental journals, including the Drug Information Handbook for Dentistry2 and the Journal for Practical Hygiene.3 According to a study in the Journal of Esthetic and Restorative Dentistry, the current top–selling OTC medication reduces cold sore healing time by only one day. The average cold sore lasts 10 to 12 days. When used properly, Viroxyn Professional Use heals the cold sore in only three days, while mitigating future outbreaks with early use.4 

In addition to providing pain relief within an hour for most patients, Viroxyn Professional Use helps prevent the spread of the dangerous HSV–1 virus. The patented system allows dental professionals or patients to treat the cold sore without ever touching the affected area. The patented application system combines a local anesthetic to numb the cold sore, making it possible to address the cold more aggressively. A micro–brush is then used to sluff off dead skin, allowing the anti–viral agent to attack the virus more directly. Key benefits include:

  • Immediate Pain Relief: The 7.5% benzocaine anesthetic quickly numbs the site, making it possible to address the cold sore itself.
  • Faster Healing Time: Viroxyn Professional Use utilizes a pharmacology that acts to disrupt the lipid envelope of the cold sore and effectively deliver the active ingredient directly to the site of the virus.
  • Complete Protection: The no–touch, easy–to–use treatment helps prevents disease transmission and exposure to HSV–1 for both patient and practitioner.

"Time is a valued asset. A cold sore can be debilitating, causing intense pain and disfigurement that disrupts a person's daily routine for up to two weeks,"Steve Anderson, founder and president of the Total Patient Service Institute, said. "Viroxyn Professional Use gives patients back time they would have lost. Getting patients back to the day–to–day means less appointment cancellations, which disrupt practice schedules and revenue flow."

Viroxyn Professional Use is available exclusively through healthcare providers. Make sure to visit Viroxyn Professional Use during this year's American Dental Association Annual Session at booth 5464. To place an order, call Quadex Labs, the maker of Viroxyn Professional Use, at 866-200-1232, or visit

Follow us on Twitter @ViroxynProUse and Like us on Facebook!

  1. Viroxin is an over–the–counter patented approach to treating cold sores with 5 percent benzocaine.
  2. Drug Information Handbook for Dentistry, 17th Ed, Wynn R, Meiller T, Crossley H, 2011 — 2012, Lexicomp, Hudson, OH p 1990.
  3. Spivakovsky S, Kerr R, Ship J, Diagnosis and Management of Recurrent Aphthous Ulcers and Recurrent Oral herpes, Journal of Practical Hygiene, July August, 2005 14(6) p. 11
  4. McCarthy J, Browning W, Teerlink C, Veit G, Treatment of Herpes Labialis: Comparison of Two OTC Drugs and Untreated Controls, Journal of Esthetic and Restorative Dentistry, 2012, 24(2) p103–109.